美国FDA批准的小分子作为抗炎药物的十年:最近的趋势和关于"工业"视角的评论
Vikrant Mehta1, Ashish Ranjan Dwivedi2, Abhilash Ludhiadch3
1Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, Texas, 78229, USA.
European journal of medicinal chemistry
|November 24, 2023
概括
本综述总结了USFDA批准的抗炎药物从2013-2023年,专注于小分子,生物制剂和宏分子. 它还探索了更绿色的合成路径和化学间隔,用于新药发现.
科学领域:
- 药理学和药物化学 药理学和药物化学
- 药物发现和开发 药物发现和开发
背景情况:
- 炎症是一种关键的防御机制,涉及NF-kB,MAPK和JAK-STAT等途径.
- 关键酶如循环氧化酶 (COX) 也在炎症过程中发挥着重要作用.
- 了解这些途径和标记物对于开发有效的抗炎疗法至关重要.
研究的目的:
- 从2013-2023年编制和审查USFDA批准的抗炎药物.
- 讨论小分子,生物和大分子,重点关注更绿色的合成路径.
- 为抗炎药物设计提供化学间隔参数的洞察力.
主要方法:
- 2013年至2023年间美国FDA批准的药物的综合文献审查.
- 对药物类别的分析,包括小分子,生物制剂和大分子.
- 检查合成路径,专注于绿色化学原则.
- 讨论与抗炎药物发现相关的化学间隔参数.
主要成果:
- 在指定期限内确定批准的抗炎药物.
- 综述各种药物模式及其批准的应用.
- 强调药物制造中更绿色的合成方法.
- 对影响药物疗效的结构特征的分析.
结论:
- 该评论为药物化学家和药物发现科学家提供了宝贵的资源.
- 它强调了绿色合成和化学间隔在开发下一代抗炎药物的重要性.
- 该汇编为推进抗炎药物研究提供了新的视角.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Inflammatory Bowel Disease IV: Pharmacological Management
132
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
132
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
146
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
146
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168


